CB1 is distributed broadly throughout the central nervous system1−3 and human genetic variants of CB1 are linked to manypsychiatric disorders (substance dependence, eating disorders, schizophrenia,4 pain sensitivity, sleep and memory disorders),5 and altered CB1 signaling is observedin other disorders (alcohol use disorder, schizophrenia, post-traumaticstress disorder, eating disorders,6 andParkinson’s disease).7 For thisreason, the agonism or antagonism of CB1 is a key therapeutictarget for drug or gene therapy development. This evidence concerns the gene CNR1 and glycogen storage disease VI.